PDB36 LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES
Keyword(s):
2012 ◽
Vol 15
(4)
◽
pp. 654-663
◽
Keyword(s):
2019 ◽
Vol 25
(6)
◽
pp. 669-680
Keyword(s):
2016 ◽
Vol 33
(2)
◽
pp. 231-238
◽
Keyword(s):
2021 ◽
Vol 116
(1)
◽
pp. S37-S37
Keyword(s):
2012 ◽
Vol 6
(3)
◽
pp. 686-694
◽
Keyword(s):
Keyword(s):
2012 ◽
Vol 15
(6)
◽
pp. 1039-1050
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):